Glenmark Pharmaceuticals launches TEVIMBRA in India
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The company will provide the necessary response to USFDA within stipulated 15 days
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Subscribe To Our Newsletter & Stay Updated